(Q35170197)

English

Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells (English)

1 reference

Europe PubMed Central

6 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Allison W Welsh

1

1 reference

Europe PubMed Central

6 August 2017

Christopher B Moeder

2

1 reference

Europe PubMed Central

6 August 2017

Sudha Kumar

3

1 reference

Europe PubMed Central

6 August 2017

Peter Gershkovich

4

1 reference

Europe PubMed Central

6 August 2017

Elaine T Alarid

5

1 reference

Europe PubMed Central

6 August 2017

Malini Harigopal

6

1 reference

Europe PubMed Central

6 August 2017

Bruce G Haffty

7

1 reference

Europe PubMed Central

6 August 2017

David L Rimm

8

1 reference

Europe PubMed Central

6 August 2017

language of work or name

0 references

publication date

27 June 2011

1 reference

Europe PubMed Central

6 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

6 August 2017

29

1 reference

Europe PubMed Central

6 August 2017

22

1 reference

Europe PubMed Central

6 August 2017

2978-2984

1 reference

Europe PubMed Central

6 August 2017

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Current issues in ER and HER2 testing by IHC in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Comparison of estrogen receptor results from pathology reports with results from central laboratory testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

13 July 2018

Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

27 September 2018

Commentary: hormone receptor testing in breast cancer: a distress signal from Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

27 September 2018

Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

27 September 2018

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157961

27 September 2018

Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/21709197

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21709197

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen receptor expression in breast cancer: we cannot ignore the shades of gray

1 reference

https://pubmed.ncbi.nlm.nih.gov/21709197

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.32.9706

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35170197&oldid=1966907150"